fda glp-1 warning news november 2025 Covering Drugs: Employers' Top Questions Answered – Sequoia FDA warns Novo Nordisk of

Target-driven exit rules: transition the clinical mindset from treating for a trial period to exiting upon target achievement. For instance, a 36 months metabolic optimization window should be pre-set to achieve a clinically meaningful weight-loss threshold and improve IR markers

Data-driven clustering studies suggest that conventional diagnostic labels can mask biologically coherent subgroups

Future studies are needed to determine if there is a benefit in NASH reduction or fibrosis regression

Treatment Support May be used within a broader clinician-guided approach to weight management and related health goals

2008 Sep

Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction-associated steatotic liver disease, and other cardio-kidney-metabolic conditions